What the evidence tells us about Tylenol, leucovorin, and autism

The potential connections between medication use during pregnancy and developmental disorders have generated significant discussions among healthcare professionals and the public alike. Recently, the administration, represented by President Trump and Robert F. Kennedy Jr., the Secretary of Health and Human Services, has highlighted two intriguing topics: the possible link between Tylenol (acetaminophen) consumption during pregnancy and autism spectrum disorder (ASD), and the potential benefits of leucovorin, a form of folic acid, for improving verbal abilities in some individuals with autism.

While these topics are not new—research on Tylenol’s implications for neurodevelopment and the effects of leucovorin on autism have circulated for over a decade—it’s crucial to approach them with a critical lens. The complexity of autism spectrum disorder and its varying manifestations complicates our understanding of these potential correlations.

Many researchers examining the link between Tylenol usage in pregnancy and autism have not found conclusive evidence supporting a direct relationship. Contrarily, some researchers suggest that the common analgesic is not likely to contribute to autism risk. Nevertheless, the academic community remains divided. A recent review of 46 studies published in Environmental Health includes opinions from experts at Harvard University, indicating that there may be a basis for caution regarding acetaminophen use in pregnant women.

According to the review, “Appropriate and immediate steps should be taken to advise pregnant women to limit acetaminophen consumption to protect their offspring’s neurodevelopment.” However, this conclusion has met with criticism regarding the soundness of the methodology employed in the study, with several autism researchers questioning its validity.

Causation or Correlation?

Numerous studies utilizing varied methodologies indicate that mothers who consume Tylenol while pregnant are statistically more likely to have children diagnosed with autism. Researchers have incorporated diverse approaches, from maternal recall of medication use to analyzing the concentration of acetaminophen byproducts in umbilical cord blood.

Although the associated risk appears modest—one analysis suggested a 5% increase in risk, while a meta-analysis indicated a 20% rise—this correlation alone cannot account for the surge in autism diagnoses over the past two decades. Many in the scientific community argue that evolving diagnostic criteria may primarily explain the increase in autism cases. The critical debate revolves around whether Tylenol could be a causal factor or whether it is merely more frequently used by those with conditions during pregnancy—such as infections and migraines—that might also be linked to autism.

Understanding this distinction represents a classic issue in scientific inquiry. For example, increased ice cream sales in summer correlate with both rising temperatures and an uptick in sunburns, but one does not cause the other.

A notable study published in JAMA last year tackled this dilemma by investigating cases where mothers used acetaminophen in one pregnancy but not in another, suggesting that shared familial factors might distort the perceived link between acetaminophen use and autism prevalence. By analyzing a massive database of 2.5 million Swedish children born between 1995 and 2019, the researchers discovered that about 186,000 had been exposed to Tylenol in utero.

According to Brian Lee, a co-author, this evidence points away from a causal relationship, suggesting that familial genetic predispositions could be paving the way for both increased use of Tylenol and the development of autism or ADHD in children. This means mothers with a genetic inclination toward these conditions are likely to experience greater pain during pregnancy and, subsequently, utilize more pain relief medications.

Criticism of the Swedish Sibling Paper

Critics of the Swedish sibling study have pointed out substantial limitations, one major concern being the notably low reported use of acetaminophen (only 7.5% compared to an expected 50%). Ann Bauer, a researcher from the University of Massachusetts, Lowell, argued that this low reporting might lead to an underestimation of risks surrounding acetaminophen use during pregnancy, prompting her and her co-authors to suggest that pregnant women should be advised on the potential risks associated with Tylenol.

This recommendation, however, raises complex issues, as alternative medications may carry more substantial risks to fetal development. The UK’s Medicines and Healthcare products Regulatory Agency recently reiterated that, based on extensive scientific evaluation, acetaminophen remains a safe and recommended option for managing pain and fever during pregnancy.

Does Leucovorin Help People with Autism?

The investigation into leucovorin presents a somewhat clearer narrative. Several smaller studies propose that leucovorin could improve verbal test performance in children diagnosed with autism. For instance, a study published in the European Journal of Pediatrics tracked 80 children aged 2 to 10 assigned to receive either leucovorin or a placebo. After 24 weeks, the leucovorin group scored an average of 1.2 points higher on a standardized autism severity scale compared to the placebo group.

Although statistically significant, the relatively small sample size raises the possibility of erroneous positive findings. To further validate these findings, researchers typically advocate for larger-scale randomized controlled trials that entail more extensive patient pools to confirm treatment efficacy and safety.

Both the inquiries into Tylenol and leucovorin present further complications; high-quality studies depend on manufacturers’ incentives to conduct them. Despite being a commonly used medication, acetaminophen, along with leucovorin, is available generically and thus, large-scale observational studies or randomized trials are less likely to be funded. This gap in research limits our understanding of both substances and their potential implications for maternal and child health.